Relmada Therapeutics, Inc. RLMD Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$19.05M+4.1% | -$19.87M-96.9% | -$10.09M-2.3% | -$9.87M+43.8% | -$17.56M+5.9% | ||
| $956.19K-59.7% | $2.37M-34.3% | $3.61M-17.1% | $4.35M+21.9% | $3.57M-46.9% | ||
| $1.76M— | —— | —— | —— | -$2.87M-261% | ||
| -$1.56M— | —— | -$36.14K+81.3% | -$193.78K+91.2% | -$2.19M— | ||
| $402.43K— | —— | —— | —— | -$290.05K— | ||
| -$540.1K-390% | $186.05K+165% | $70.28K+609% | -$13.8K-109% | $155.73K— | ||
| -$15.07M-3.2% | -$14.6M-117% | -$6.72M-5.0% | -$6.4M+64.6% | -$18.07M-105% | ||
| $149.52M+80.6% | $82.79M+35,289% | $233.93K-27.2% | $321.46K-34.1% | $487.92K-25.5% | ||
| $14.29M+144% | $5.86M-16.2% | $6.99M-0.2% | $7M-55.8% | $15.85M+32.1% | ||
| $8.09M+0.2% | $8.07M+100.0% | $4.04M+43.2% | $2.82M-76.4% | $11.95M+8.6% | ||
| -$135.23M-75.8% | -$76.93M-1,239% | $6.75M+1.1% | $6.68M-56.5% | $15.36M+35.4% | ||
| $3.36M— | —— | —— | —— | —— | ||
| $160M+583% | $23.41M0.0% | $23.41M0.0% | $23.41M0.0% | $23.41M+6,378% | ||
| $156.57M+67.2% | $93.64M— | —— | —— | —— | ||
| $6.28M— | —— | —— | —— | -$2.71M— | ||
| $956.2K-70.8% | $3.28M-9.2% | $3.61M-17.1% | $4.35M+21.9% | $3.57M-46.9% | ||
| $402.43K— | —— | —— | —— | -$290.05K— | ||
| —— | —— | —— | —— | $905.23K— | ||
| -$9.87K+90.9% | -$107.92K-32.5% | -$81.44K-273% | $47.2K-25.0% | $62.95K+54.1% | ||
| -$9.87K— | —— | —— | —— | $62.95K— | ||
| $2.68M— | —— | —— | $24.61K+710% | $3.04K+172% | ||
| -$540.1K— | —— | —— | —— | $155.73K— | ||
| $149.52M+80.6% | $82.79M+35,289% | $233.93K-27.2% | $321.46K-34.1% | $487.92K-25.5% | ||
| $14.29M+144% | $5.86M-16.2% | $6.99M-0.2% | $7M-55.8% | $15.85M+32.1% | ||
| $65.65K+260% | $18.26K0.0% | $18.26K0.0% | $18.26K0.0% | $18.26K-89.4% | ||
| 2.1M— | —— | —— | —— | —— | ||
| —— | 0%— | —— | —— | —— | ||
| —— | -2%— | —— | —— | —— | ||
| $11.37M-7.2% | $12.26M+94.9% | $6.29M-15.0% | $7.4M+18.1% | $6.27M-22.4% | ||
| $959.76K+148% | $387.23K+56.8% | $247.01K-23.2% | $321.46K-27.0% | $440.29K-32.7% | ||
| $409.8K-11.9% | $465.35K+97.3% | $235.85K-33.5% | $354.86K-46.1% | $658.97K+57.5% | ||
| —— | —— | —— | —— | 10%— | ||
| —— | —— | —— | —— | $3.5M— | ||
| —— | —— | —— | —— | 10%— | ||
| —— | $1.38— | —— | —— | —— | ||
| —— | 0%— | —— | —— | 0%— | ||
| -2.1M— | —— | —— | —— | —— | ||
| -$65.65K— | —— | —— | —— | —— | ||
| -$540.1K-390% | $186.05K+165% | $70.28K+609% | -$13.8K-109% | $155.73K— | ||
| 4.2M-20.8% | 5.3M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Relmada Therapeutics, Inc. generate?
- Relmada Therapeutics, Inc. (RLMD) generated -$42.8M in operating cash flow over the trailing twelve months.
- What is Relmada Therapeutics, Inc.'s free cash flow?
- After $182.1M of capital expenditures, Relmada Therapeutics, Inc.'s free cash flow was -$209.9M over the trailing twelve months, down 116.5% year over year.
- Where does Relmada Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Relmada Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.